-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] With the normalization of centralized procurement and the advancement of medical insurance cost control, in the long run, the growth of generic drugs will be sluggish, and companies that focus on innovation will gain continuous endogenous power
.
In this context, the pharmaceutical industry has accelerated the pace of innovation and transformation
.
However, for pharmaceutical companies, the growth of innovative drug revenue is inseparable from the company's continuous investment in research and development
.
According to the mid-year report of innovative drug companies in 2022, more than 70% of innovative drug companies have increased their R&D investment, and seven companies including BeiGene, Hengrui, Junshi Biopharmaceuticals, China Biopharmaceuticals, CSPC R&D, and Chi-Med have all invested more than 1 billion yuan
.
Among them, BeiGene's research and development expenses in the first half of the year exceeded 5 billion yuan, reaching 5.
016 billion yuan, an increase of 20.
82% compared with the same period of the previous year
.
It is reported that the company's research and development investment is used for pre-bed research, clinical trials, and cooperative research and development of product pipelines
.
Hengrui Medicine, which followed closely behind, accumulated R&D investment of 2.
909 billion yuan in the first half of the year, an increase of 12.
74% year-on-year.
The proportion of R&D investment in sales revenue increased to a record high of 28.
44% year-on-year, of which expensed R&D investment was 2.
184 billion yuan, and R&D expenses were 2.
184 billion yuan.
The proportion of sales revenue increased to 21.
36% year-on-year
.
During the reporting period, the innovative drug Revelutamide Tablets was approved for marketing, and Pyrotinib Maleate Tablets were approved for marketing in 2 lower indications
.
In the first half of the year, Fosun Pharma continued to strengthen innovative research and development, with R&D investment of 2.
399 billion yuan, an increase of 22.
77% year-on-year, of which R&D expenses were 1.
818 billion yuan, an increase of 256 million yuan or 16.
39% year-on-year
.
In the first half of this year, Fosun's innovative PD-L1 drug slulimumab injection was approved for marketing; rituximab injection, an innovative indication for rheumatoid arthritis, was approved for marketing
.
In addition, the company has more than 260 projects under development, including innovative drugs, biosimilars, generic drugs, and consistency evaluation
.
In the first half of the year, Sino Biopharm continued to accelerate its innovation drive and transformation, with a total R&D investment of 2.
19 billion yuan, an increase of 16.
5% year-on-year, and a record high of 14.
4%
.
At the same time, innovative drugs have become more and more prominent in driving the company's performance, with a total revenue of 3.
49 billion yuan, accounting for 22.
9% of revenue, a year-on-year increase of 14.
2%
.
The semi-annual report also shows that the revenue of innovative drugs will account for 24% of the total this year, and the revenue of innovative drugs may exceed the 10 billion yuan mark in 2023
.
CSPC's R&D investment in the first half of the year reached 1.
884 billion yuan, a year-on-year increase of 16.
8%
.
It is reported that the company has continuously increased investment in research and development, and more than 50 innovative products are in the clinical research stage
.
Up to now, the company has 7 innovative drug products approved for marketing, including mitoxantrone hydrochloride, butylphthalide, butylphthalide, Anfulike, filgrastim follow-on biologic, paclitaxel, and beta-elemene
.
Junshi Bio's R&D investment in the first half of the year was 1.
062 billion yuan, a year-on-year increase of 12.
14%
.
The total investment in research and development accounted for 112.
28% of the operating income, an increase of 67.
48 percentage points
.
The company stated that during the reporting period, the company continued to promote research and development projects according to the research and development process, continuously enriched and expanded the pipeline of products under research through independent research and development and cooperative development/introduction of rights and interests, rapidly promoted the progress of projects that have entered the clinical stage, and actively reserved and Facilitate the development of preclinical programs
.
Chi-Med's R&D investment in the first half of the year also exceeded 1 billion yuan, a year-on-year increase of 47.
6%
.
As an innovative biopharmaceutical company in the commercialization stage, the company has a R&D innovation platform and a commercial platform.
At present, the company has 3 innovative drugs approved for marketing, namely surufatinib, fruquintinib and sivotinib
.
The company also has 3 innovative drugs in the global late-stage development stage and 11 innovative drugs in the clinical stage
.
In addition, the company has completed 4 registration studies, 13 are in progress, and will initiate 5+ registration studies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In this context, the pharmaceutical industry has accelerated the pace of innovation and transformation
.
However, for pharmaceutical companies, the growth of innovative drug revenue is inseparable from the company's continuous investment in research and development
.
According to the mid-year report of innovative drug companies in 2022, more than 70% of innovative drug companies have increased their R&D investment, and seven companies including BeiGene, Hengrui, Junshi Biopharmaceuticals, China Biopharmaceuticals, CSPC R&D, and Chi-Med have all invested more than 1 billion yuan
.
Among them, BeiGene's research and development expenses in the first half of the year exceeded 5 billion yuan, reaching 5.
016 billion yuan, an increase of 20.
82% compared with the same period of the previous year
.
It is reported that the company's research and development investment is used for pre-bed research, clinical trials, and cooperative research and development of product pipelines
.
Hengrui Medicine, which followed closely behind, accumulated R&D investment of 2.
909 billion yuan in the first half of the year, an increase of 12.
74% year-on-year.
The proportion of R&D investment in sales revenue increased to a record high of 28.
44% year-on-year, of which expensed R&D investment was 2.
184 billion yuan, and R&D expenses were 2.
184 billion yuan.
The proportion of sales revenue increased to 21.
36% year-on-year
.
During the reporting period, the innovative drug Revelutamide Tablets was approved for marketing, and Pyrotinib Maleate Tablets were approved for marketing in 2 lower indications
.
In the first half of the year, Fosun Pharma continued to strengthen innovative research and development, with R&D investment of 2.
399 billion yuan, an increase of 22.
77% year-on-year, of which R&D expenses were 1.
818 billion yuan, an increase of 256 million yuan or 16.
39% year-on-year
.
In the first half of this year, Fosun's innovative PD-L1 drug slulimumab injection was approved for marketing; rituximab injection, an innovative indication for rheumatoid arthritis, was approved for marketing
.
In addition, the company has more than 260 projects under development, including innovative drugs, biosimilars, generic drugs, and consistency evaluation
.
In the first half of the year, Sino Biopharm continued to accelerate its innovation drive and transformation, with a total R&D investment of 2.
19 billion yuan, an increase of 16.
5% year-on-year, and a record high of 14.
4%
.
At the same time, innovative drugs have become more and more prominent in driving the company's performance, with a total revenue of 3.
49 billion yuan, accounting for 22.
9% of revenue, a year-on-year increase of 14.
2%
.
The semi-annual report also shows that the revenue of innovative drugs will account for 24% of the total this year, and the revenue of innovative drugs may exceed the 10 billion yuan mark in 2023
.
CSPC's R&D investment in the first half of the year reached 1.
884 billion yuan, a year-on-year increase of 16.
8%
.
It is reported that the company has continuously increased investment in research and development, and more than 50 innovative products are in the clinical research stage
.
Up to now, the company has 7 innovative drug products approved for marketing, including mitoxantrone hydrochloride, butylphthalide, butylphthalide, Anfulike, filgrastim follow-on biologic, paclitaxel, and beta-elemene
.
Junshi Bio's R&D investment in the first half of the year was 1.
062 billion yuan, a year-on-year increase of 12.
14%
.
The total investment in research and development accounted for 112.
28% of the operating income, an increase of 67.
48 percentage points
.
The company stated that during the reporting period, the company continued to promote research and development projects according to the research and development process, continuously enriched and expanded the pipeline of products under research through independent research and development and cooperative development/introduction of rights and interests, rapidly promoted the progress of projects that have entered the clinical stage, and actively reserved and Facilitate the development of preclinical programs
.
Chi-Med's R&D investment in the first half of the year also exceeded 1 billion yuan, a year-on-year increase of 47.
6%
.
As an innovative biopharmaceutical company in the commercialization stage, the company has a R&D innovation platform and a commercial platform.
At present, the company has 3 innovative drugs approved for marketing, namely surufatinib, fruquintinib and sivotinib
.
The company also has 3 innovative drugs in the global late-stage development stage and 11 innovative drugs in the clinical stage
.
In addition, the company has completed 4 registration studies, 13 are in progress, and will initiate 5+ registration studies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
